A Phase 3 interventional study of Mexidol (Ethylmethylhydroxypyridine Succinate) and Placebo in Ischemic Stroke, sponsored by Pharmasoft. Completed at 17 sites in 3 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Pharmasoft · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Ischemic Stroke with a site in Russia — 12 open to participants now, 12 under way, 2 of them phase 3. Ischemic Stroke · Russia.
Among the 15 studies in Ischemic Stroke with a site in Russia, this one is the only one that started in 2019, is one of 3 in phase 3, and was the 6th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →12 of the 15 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:
Supergene, LLC · Sites in Russia
Ages 18+
Pharmasoft · Sites in Russia
Ages 18–90 · Healthy volunteers
Tatchempharmpreparaty, JSC · Sites in Russia
Ages 35–80
Pirogov Russian National Research Medical University · Sites in Russia
Ages 40–80
National Society for Neurosonology and Cerebral Circulation · Sites in Russia
Ages 18–85
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 304 is above the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 120 across the 9 interventional studies, 448 across the 6 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 10 most frequent:
Pharmasoft is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Pharmasoft has 4 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
5 of the studies in Ischemic Stroke with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07912151Samara State Medical UniversityDynamic Stabilometry Combined With Transcranial Direct Current Stimulation for Balance and Motor Recovery After Ischemic Stroke | 2026-12-28 |
| NCT06175715Pirogov Russian National Research Medical UniversityGeneral Versus Regional Anesthesia for Carotid Endarterectomy at Acute Ischemic Stroke Trial | 2026-12-31 |
| NCT07520630Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports MedicineNeurophysiological Markers for Prediction of Rehabilitation Outcomes After Ischemic Stroke | 2027-03 |
| NCT07575984PharmasoftMexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke | 2027-04 |
| NCT07083986Pirogov Russian National Research Medical UniversityCarotid Endarterectomy Versus Stenting in Patients With Acute Stage of Ischemic Stroke. | 2027-05-21 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies in Ischemic Stroke with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of the clinical trial is to evaluate the efficacy and safety of Mexidol® in sequential treatment for patients in the acute and early recovery periods of ischemic stroke compared to placebo. The effect of adding Mexidol® to standard therapy on the degree of impairment of vital functions was assessed including the degree of disability (according to the Modified Rankin Scale, mRS), the severity of neurological symptoms (according to the National Institutes of Health Stroke Scale, NIHSS) and the level of mobility of patients (according to the Rivermead Mobility Index).
As the main purpose of the clinical study is to evaluate safety and efficacy of a neuroprotector (Mexidol®), it was crucial to develop strict protocol requirements that would help to avoid the challenges of estimation of neuroprotective effect for stroke therapy. The current treatment options for stroke are still limited and do not take into account rehabilitation period and patients' further quality of life.
As per protocol requirements, 313 participants were screened, 304 participants met all comprehensive eligibility criteria, 25 participants dropped out during the clinical trial period. The Modified Rankin Scale (mRS) was selected as the most representative primary outcome measuring tool due to the adequate representation of functional outcome. Additionally, the neuroprotective efficacy of Mexidol® was assessed for its ability to reduce stroke-related neurologic deficit, to improve mobility after stroke and to influence cognitive impairment and mood disorder symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Mexidol® IV 500 mg 2 times a day for 10 days, then Mexidol® FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days
Drug: Mexidol (Ethylmethylhydroxypyridine Succinate)
Participants received Placebo matching Mexidol® IV 500 mg 2 times a day for 10 days, then Mexidol® FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days
Drug: Placebo
50 mg/ml IV solution, 250 mg tablets
Placebo IV solution, Placebo tablets
Change From Baseline in the Modified Rankin Scale (mRS) Scores at the End of the Course of Therapy
The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 0, Day 0-1 Scores).
Time frame: Baseline, Day 71
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores >3 (Higher Degree of Disability) at the End of the Course of Therapy
The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\].
Time frame: Day 71
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores 0-1 (Normal or Lower Degree of Disability) at the End of the Course of Therapy
The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\].
Time frame: Day 71
Change From Baseline in the National Institutes of Health Stroke Scale (NIHSS) Score at the End of the Course of Therapy
The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (severe stroke), with the minimum score being a 0 (no stroke symptoms) \[43 point scale: min value 0, max value 42, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 0, Day 0-1 Scores).
Time frame: Baseline, Day 71
Change From Baseline in the Rivermead Mobility Index (RMI) Score at the End of the Course of Therapy
The Rivermead Mobility Index (RMI) is a hierarchical mobility scale used in neurological rehabilitation. It includes 15 items related to bed mobility, transfers, walking, stair use, and running. The test is comprised of 14 questions, and the patient is then asked to stand for 10 seconds without any aid. Each response is scored yes or no with 1 point for each yes answer. The scores are summed with a range from 0 (poor mobility) to 15 (excellent mobility) \[16 point scale: min value 0, max value 15, higher scores mean a better outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).
Time frame: Baseline, Day 71
Change From Baseline in the Montreal Cognitive Assessment (MoCA) Score at the End of the Course of Therapy
The Montreal Cognitive Assessment (MoCA) is a 30-point validated scale that covers multiple cognitive domains including spatiotemporal orientation, sustained attention, visuospatial function, executive function, verbal memory, language, naming, and abstract thinking \[31 point scale: min value 0, max value 30, higher scores mean a better outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).
Time frame: Baseline, Day 71
Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain ANXIETY (HADS-A), at the End of the Course of Therapy
The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure that was specifically designed to screen for distinct dimensions of anxiety and depression in nonpsychiatric hospital departments; somatic symptoms were excluded \[22 point scale for each domain (Anxiety or Depression): min value 0, max value 21, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).
Time frame: Baseline, Day 71
Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain DEPRESSION (HADS-D), at the End of the Course of Therapy
The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure that was specifically designed to screen for distinct dimensions of anxiety and depression in nonpsychiatric hospital departments; somatic symptoms were excluded \[22 point scale for each domain (Anxiety or Depression): min value 0, max value 21, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).
Time frame: Baseline, Day 71
| Milestone | Mexidol® | Placebo |
|---|---|---|
| Started | 152 | 152 |
| Completed | 141 | 138 |
| Not completed | 11 | 14 |
The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 0, Day 0-1 Scores).
| score on a scale | Mexidol® | Placebo |
|---|---|---|
| Change From Baseline in the Modified Rankin Scale (mRS) Scores at the End of the Course of Therapy | -2.45 (-2.70 to -2.23) | -2.01 (-2.25 to -1.87) |
The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\].
| Participants | Mexidol® | Placebo |
|---|---|---|
| Percentage of Subjects Having Modified Rankin Scale (mRS) Scores >3 (Higher Degree of Disability) at the End of the Course of Therapy | 22 | 39 |
The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\].
| Participants | Mexidol® | Placebo |
|---|---|---|
| Percentage of Subjects Having Modified Rankin Scale (mRS) Scores 0-1 (Normal or Lower Degree of Disability) at the End of the Course of Therapy | 85 | 57 |
The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (severe stroke), with the minimum score being a 0 (no stroke symptoms) \[43 point scale: min value 0, max value 42, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 0, Day 0-1 Scores).
| score on a scale | Mexidol® | Placebo |
|---|---|---|
| Change From Baseline in the National Institutes of Health Stroke Scale (NIHSS) Score at the End of the Course of Therapy | -7 (-9 to -6) | -7 (-8 to -5) |
The Rivermead Mobility Index (RMI) is a hierarchical mobility scale used in neurological rehabilitation. It includes 15 items related to bed mobility, transfers, walking, stair use, and running. The test is comprised of 14 questions, and the patient is then asked to stand for 10 seconds without any aid. Each response is scored yes or no with 1 point for each yes answer. The scores are summed with a range from 0 (poor mobility) to 15 (excellent mobility) \[16 point scale: min value 0, max value 15, higher scores mean a better outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).
| score on a scale | Mexidol® | Placebo |
|---|---|---|
| Change From Baseline in the Rivermead Mobility Index (RMI) Score at the End of the Course of Therapy | 10 (7 to 12) | 9 (7 to 11) |
The Montreal Cognitive Assessment (MoCA) is a 30-point validated scale that covers multiple cognitive domains including spatiotemporal orientation, sustained attention, visuospatial function, executive function, verbal memory, language, naming, and abstract thinking \[31 point scale: min value 0, max value 30, higher scores mean a better outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).
| score on a scale | Mexidol® | Placebo |
|---|---|---|
| Change From Baseline in the Montreal Cognitive Assessment (MoCA) Score at the End of the Course of Therapy | 4 (2 to 6) | 3 (1 to 6) |
The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure that was specifically designed to screen for distinct dimensions of anxiety and depression in nonpsychiatric hospital departments; somatic symptoms were excluded \[22 point scale for each domain (Anxiety or Depression): min value 0, max value 21, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).
| score on a scale | Mexidol® | Placebo |
|---|---|---|
| Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain ANXIETY (HADS-A), at the End of the Course of Therapy | -2 (-5 to 0) | -1 (-4 to 0) |
The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure that was specifically designed to screen for distinct dimensions of anxiety and depression in nonpsychiatric hospital departments; somatic symptoms were excluded \[22 point scale for each domain (Anxiety or Depression): min value 0, max value 21, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).
| score on a scale | Mexidol® | Placebo |
|---|---|---|
| Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain DEPRESSION (HADS-D), at the End of the Course of Therapy | -2 (-4 to 0) | -1 (-4 to 0) |
Collected over Throughout the study [From Day 1 up to Day 71]. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mexidol® | 2/152 (1.3%) | 6/152 (3.9%) | 36/152 (23.7%) |
| Placebo | 1/152 (0.7%) | 4/152 (2.6%) | 39/152 (25.7%) |
| Event | Mexidol® | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 0/152 | 3/152 |
| PneumoniaInfections and infestations | 1/152 | 0/152 |
| Ischaemic strokeNervous system disorders | 1/152 | 0/152 |
| Brain oedemaNervous system disorders | 1/152 | 0/152 |
| Cerebral infarctionNervous system disorders | 1/152 | 0/152 |
| Pneumonia viralInfections and infestations | 1/152 | 0/152 |
| COVID-19 pneumoniaInfections and infestations | 1/152 | 0/152 |
| Cerebrovascular accidentNervous system disorders | 0/152 | 1/152 |
| Event | Mexidol® | Placebo |
|---|---|---|
| Blood pressure increasedInvestigations | 3/152 | 5/152 |
| HeadacheNervous system disorders | 5/152 | 2/152 |
| TachycardiaCardiac disorders | 3/152 | 4/152 |
| COVID-19Infections and infestations | 3/152 | 2/152 |
| DiarrhoeaGastrointestinal disorders | 2/152 | 1/152 |
| Upper respiratory tract infectionInfections and infestations | 1/152 | 2/152 |
| Back painMusculoskeletal and connective tissue disorders | 2/152 | 1/152 |
| InsomniaPsychiatric disorders | 2/152 | 0/152 |
| Abdominal pain upperGastrointestinal disorders | 0/152 | 1/152 |
| ConstipationGastrointestinal disorders | 0/152 | 1/152 |
| Age, Continuous(years) | Mexidol® | Placebo | Total |
|---|---|---|---|
| Mean | 62.45 ± 7.88 | 62.61 ± 7.49 | 62.53 ± 7.68 |
| Sex: Female, Male(Participants) | Mexidol® | Placebo | Total |
|---|---|---|---|
| Female | 48 | 52 | 100 |
| Male | 104 | 100 | 204 |
| Race (NIH/OMB)(Participants) | Mexidol® | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 13 | 16 | 29 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 139 | 136 | 275 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Mexidol® | Placebo | Total |
|---|---|---|---|
| Uzbekistan | 10 | 10 | 20 |
| Kazakhstan | 10 | 10 | 20 |
| Russia | 132 | 132 | 264 |
| Modified Rankin Scale (mRS)(units on a scale) | Mexidol® | Placebo | Total |
|---|---|---|---|
| Mean | 3.90 ± 0.50 | 3.94 ± 0.48 | 3.92 ± 0.49 |
| Percentage of Subjects Having Modified Rankin Scale (mRS) Scores >3 (Higher Degree of Disability)(Participants) | Mexidol® | Placebo | Total |
|---|---|---|---|
| Count of participants | 152 | 152 | 304 |
| Percentage of Subjects Having Modified Rankin Scale (mRS) Scores 0-1 (Normal or Lower Degree of Disa(Participants) | Mexidol® | Placebo | Total |
|---|---|---|---|
| Count of participants | 0 | 0 | 0 |
| National Institutes of Health Stroke Scale (NIHSS)(units on a scale) | Mexidol® | Placebo | Total |
|---|---|---|---|
| Median | 9 (9 to 11) | 10 (9 to 10) | 9.5 (9 to 10.5) |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2019 to primary completion in Aug 2023, 45 months.
Results were first posted in Dec 2025, 2 years 3 months after primary completion.
Of 165 phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's 45 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emoxypine succinate
Pharmasoft